Nuformix plc (LON:NFX – Get Free Report)’s stock price rose 11.8% during trading on Tuesday . The company traded as high as GBX 0.10 ($0.00) and last traded at GBX 0.09 ($0.00). Approximately 56,631,465 shares changed hands during trading, a decline of 22% from the average daily volume of 72,646,188 shares. The stock had previously closed at GBX 0.08 ($0.00).
Nuformix Trading Up 10.5 %
The company has a debt-to-equity ratio of 1.17, a current ratio of 1.12 and a quick ratio of 3.35. The business’s 50-day moving average is GBX 0.06 and its 200 day moving average is GBX 0.09. The firm has a market capitalization of £688,220.40, a P/E ratio of -1.63 and a beta of 1.22.
Nuformix (LON:NFX – Get Free Report) last released its earnings results on Wednesday, January 29th. The company reported GBX (0.46) (($0.01)) EPS for the quarter.
Nuformix Company Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Featured Stories
- Five stocks we like better than Nuformix
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Merck: 4 No-Brainer Reasons to Buy This Dip
- What Is WallStreetBets and What Stocks Are They Targeting?
- Ackman Announces Major Stake in Uber: Should You Follow His Lead?
- Ride Out The Recession With These Dividend Kings
- Wells Fargo Upgraded These 3 Stocks—Here’s Why They Stand Out
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
